Denis Burger - Cytodyn Vice Chairman and Chief Science Officer

CYDY Stock  USD 0.16  0.01  5.88%   

Chairman

Dr. Denis R. Burger, Ph.D., is Director of CytoDyn Inc. Consideration of his nomination was recommended to the Nominating and Governance Committee by the Companys Chief Executive Officer. He is also currently a director of Lorus Therapeutics, Inc., a cancer therapeutics company listed on the TSX, and serves on its audit committee. Dr. Burger cofounded Trinity Biotech PLC, a NASDAQ listed diagnostic company, in June 1992, served as its Chairman from June 1992 to May 1995, and is currently lead independent director. Until March 2007, he was Chairman and Chief Executive Officer of AVI Biopharma Inc., a NASDAQ listed RNA therapeutics company. He was also a cofounder of Epitope Inc., serving as its Chairman from 1981 to 1990. Dr. Burger previously held a professorship in the Department of Microbiology and Immunology and Surgery at the Oregon Health and Sciences University in Portland. Dr. Burger received his undergraduate degree in Bacteriology and Immunology from the University of California, Berkeley and his MS and Ph.D. degrees in Microbiology and Immunology from the University of Arizona. Dr. Burger brings significant biotechnology company experience and operational expertise to our Board, as well as a local presence for in person consultations with management. . since 2014.
Age 79
Tenure 10 years
Phone360 980 8524
Webhttps://www.cytodyn.com
Burger received his undergraduate degree in Bacteriology and Immunology from the University of California in Berkeley and his MS and Ph.D. degrees in Microbiology and Immunology from the University of Arizona.

Cytodyn Management Efficiency

The company has return on total asset (ROA) of (1.4819) % which means that it has lost $1.4819 on every $100 spent on assets. This is way below average. Cytodyn's management efficiency ratios could be used to measure how well Cytodyn manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 37.35 M in liabilities. Cytodyn has a current ratio of 0.08, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Cytodyn until it has trouble settling it off, either with new capital or with free cash flow. So, Cytodyn's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cytodyn sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cytodyn to invest in growth at high rates of return. When we think about Cytodyn's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 11 records

CHAIRMAN Age

Leonard LauferAlbertsons Companies
53
Wesley TaylorAlbertsons Companies
72
Thomas BradburySmith Douglas Homes
79
Elkin PianimAlbertsons Companies
N/A
John WarehimeHanover Foods
86
John EavesAlbertsons Companies
57
Nick CaporellaNational Beverage Corp
88
Philip HeasleyAlbertsons Companies
65
Kamal HatoumBBB Foods
60
James ChapmanAlbertsons Companies
53
Christopher AtayanAMCON Distributing
64
CytoDyn Inc. operates as a clinical-stage biotechnology company. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington. Cytodyn operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 23 people. Cytodyn [CYDY] is traded as part of a regulated electronic over-the-counter service offered by the NASD.

Management Performance

Cytodyn Leadership Team

Elected by the shareholders, the Cytodyn's board of directors comprises two types of representatives: Cytodyn inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cytodyn. The board's role is to monitor Cytodyn's management team and ensure that shareholders' interests are well served. Cytodyn's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cytodyn's outside directors are responsible for providing unbiased perspectives on the board's policies.
Bernie PMP, VP Operations
Denis Burger, Vice Chairman and Chief Science Officer
Scott Kelly, Chairman of the Board
Nitya Ray, CTO and Head of Process Sciences, Manufacturing & Supply Chain
Carl Dockery, Director
Bruce Montgomery, Independent Director
Michael Mulholland, CFO, Treasurer, Corporate Secretary
David Welch, Director
Antonio CPA, Treasurer CFO
Nader Pourhassan, CEO and President and Director
Richard Pestell, Vice Chairman of the Board and Chief Medical Officer
Cyrus MBA, President
George Bitar, Head Director
Marek Ciszewski, Managing Director
Jordan Naydenov, Independent Director
Anthony Caracciolo, Chairman of the Board
Robert Schatz, Managing Director
Gregory Gould, Independent Director
Kush Dhody, VP Operations
Cristina Leon, Investors
Michael Klump, Independent Director

Cytodyn Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is Cytodyn a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Cytodyn in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Cytodyn's short interest history, or implied volatility extrapolated from Cytodyn options trading.

Pair Trading with Cytodyn

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cytodyn position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cytodyn will appreciate offsetting losses from the drop in the long position's value.

Moving against Cytodyn OTC Stock

  0.48MSFT Microsoft Fiscal Quarter End 31st of March 2024 PairCorr
  0.47TRV The Travelers Companies Fiscal Quarter End 31st of March 2024 PairCorr
  0.47VZ Verizon Communications Aggressive PushPairCorr
  0.42IBM International Business Fiscal Quarter End 31st of March 2024 PairCorr
The ability to find closely correlated positions to Cytodyn could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cytodyn when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cytodyn - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cytodyn to buy it.
The correlation of Cytodyn is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cytodyn moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cytodyn moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cytodyn can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytodyn. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.
Note that the Cytodyn information on this page should be used as a complementary analysis to other Cytodyn's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..

Complementary Tools for Cytodyn OTC Stock analysis

When running Cytodyn's price analysis, check to measure Cytodyn's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytodyn is operating at the current time. Most of Cytodyn's value examination focuses on studying past and present price action to predict the probability of Cytodyn's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cytodyn's price. Additionally, you may evaluate how the addition of Cytodyn to your portfolios can decrease your overall portfolio volatility.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
CEOs Directory
Screen CEOs from public companies around the world
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Money Managers
Screen money managers from public funds and ETFs managed around the world
Stocks Directory
Find actively traded stocks across global markets
Please note, there is a significant difference between Cytodyn's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytodyn is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytodyn's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.